Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.

Stefka AT, Johnson D, Rosebeck S, Park JH, Nakamura Y, Jakubowiak AJ.

Cancer Med. 2020 Jan;9(1):324-334. doi: 10.1002/cam4.2695. Epub 2019 Nov 12.

2.

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA.

Br J Haematol. 2019 Aug;186(4):549-560. doi: 10.1111/bjh.15969. Epub 2019 May 24.

3.

Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.

Stefka AT, Park JH, Matsuo Y, Chung S, Nakamura Y, Jakubowiak AJ, Rosebeck S.

Blood Cancer J. 2016 Aug 19;6(8):e460. doi: 10.1038/bcj.2016.71. No abstract available.

4.

API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis.

Rosebeck S, Lim MS, Elenitoba-Johnson KS, McAllister-Lucas LM, Lucas PC.

World J Biol Chem. 2016 Feb 26;7(1):128-37. doi: 10.4331/wjbc.v7.i1.128. Review.

5.

Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.

Rosebeck S, Alonge MM, Kandarpa M, Mayampurath A, Volchenboum SL, Jasielec J, Dytfeld D, Maxwell SP, Kraftson SJ, McCauley D, Shacham S, Kauffman M, Jakubowiak AJ.

Mol Cancer Ther. 2016 Jan;15(1):60-71. doi: 10.1158/1535-7163.MCT-15-0488. Epub 2015 Dec 4.

6.

Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.

Dytfeld D, Rosebeck S, Kandarpa M, Mayampurath A, Mellacheruvu D, Alonge MM, Ngoka L, Jasielec J, Richardson PG, Volchenboum S, Nesvizhskii AI, Sreekumar A, Jakubowiak AJ.

Br J Haematol. 2015 Jul;170(1):66-79. doi: 10.1111/bjh.13394. Epub 2015 Mar 30.

7.

The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling.

Rosebeck S, Rehman AO, Apel IJ, Kohrt D, Appert A, O'Donnell MA, Ting AT, Du MQ, Baens M, Lucas PC, McAllister-Lucas LM.

Oncogene. 2014 May 8;33(19):2520-30. doi: 10.1038/onc.2013.195. Epub 2013 Jun 17.

8.

From MALT lymphoma to the CBM signalosome: three decades of discovery.

Rosebeck S, Rehman AO, Lucas PC, McAllister-Lucas LM.

Cell Cycle. 2011 Aug 1;10(15):2485-96. Epub 2011 Aug 1. Review.

9.

Involvement of Noxa in mediating cellular ER stress responses to lytic virus infection.

Rosebeck S, Sudini K, Chen T, Leaman DW.

Virology. 2011 Sep 1;417(2):293-303. doi: 10.1016/j.virol.2011.06.010. Epub 2011 Jul 13.

10.

Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment.

Rosebeck S, Lucas PC, McAllister-Lucas LM.

Future Oncol. 2011 May;7(5):613-7. doi: 10.2217/fon.11.35. Review.

11.

Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.

Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, Hamoudi RA, Noels H, Sagaert X, Van Loo P, Baens M, Du MQ, Lucas PC, McAllister-Lucas LM.

Science. 2011 Jan 28;331(6016):468-72. doi: 10.1126/science.1198946. Erratum in: Science. 2011 Apr 22;332(6028):421.

12.

Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a.

Rosebeck S, Leaman DW.

Apoptosis. 2008 Apr;13(4):562-72. doi: 10.1007/s10495-008-0190-0.

PMID:
18330707

Supplemental Content

Loading ...
Support Center